SEVERE EOSINOPHILIC ASTHMA
Clinical trials for SEVERE EOSINOPHILIC ASTHMA explained in plain language.
Never miss a new study
Get alerted when new SEVERE EOSINOPHILIC ASTHMA trials appear
Sign up with your email to follow new studies for SEVERE EOSINOPHILIC ASTHMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in reversing lung damage from severe asthma
Disease control OngoingThis study tests whether benralizumab can improve lung structure and function in people with severe eosinophilic asthma who still have symptoms despite standard treatments. About 75 adults aged 18-70 will receive either the drug or a placebo for 48 weeks, followed by a 4-week che…
Matched conditions: SEVERE EOSINOPHILIC ASTHMA
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Asthma breakthrough? new study tests cutting back on meds with benralizumab
Disease control OngoingThis Phase 3b study is testing whether the drug benralizumab (Fasenra) can allow people with severe eosinophilic asthma to safely reduce their daily maintenance medications. About 504 participants aged 12-75 in China will try to step down from drugs like inhaled steroids or long-…
Matched conditions: SEVERE EOSINOPHILIC ASTHMA
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New asthma drug shows promise in late-stage trial
Disease control OngoingThis study tests a new antibody drug (called 610) for adults with severe asthma that is not well controlled by standard inhalers. About 225 participants will receive either the drug or a placebo to see if it improves lung function and reduces asthma attacks over 52 weeks. The dru…
Matched conditions: SEVERE EOSINOPHILIC ASTHMA
Phase: PHASE2 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Real-world data on benralizumab for severe asthma: what happens outside clinical trials?
Knowledge-focused OngoingThis study looks back at medical records of 197 adults in Israel who started benralizumab for severe asthma between 2019 and 2024. Researchers will count how many asthma attacks (exacerbations) patients had before and after starting the drug. The goal is to see how well benralizu…
Matched conditions: SEVERE EOSINOPHILIC ASTHMA
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Severe asthma drug may boost daily steps, study hopes
Knowledge-focused OngoingThis study looks at whether mepolizumab, a drug already used to reduce asthma attacks, can also improve physical activity and exercise tolerance in people with severe asthma. Researchers will track daily steps and activity levels in 62 adults over six months. The goal is to see i…
Matched conditions: SEVERE EOSINOPHILIC ASTHMA
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New study digs into how mepolizumab changes nose bacteria and genes in asthma patients
Knowledge-focused OngoingThis study tracks 40 people with nasal polyps and severe asthma who are taking mepolizumab, a drug that reduces inflammation. Researchers collect nose, blood, and sputum samples before treatment and at 3, 6, and 12 months to see how the drug affects symptoms, nose bacteria, and g…
Matched conditions: SEVERE EOSINOPHILIC ASTHMA
Sponsor: National and Kapodistrian University of Athens • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC